Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Lucid Diagnostics (LUCD) Research & Development (2021 - 2026)

Lucid Diagnostics filings provide 5 years of Research & Development readings, the most recent being $1.7 million for Q4 2025.

  • On a quarterly basis, Research & Development rose 18.58% to $1.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $5.7 million, a 5.24% decrease, with the full-year FY2025 number at $5.7 million, down 5.24% from a year prior.
  • Research & Development hit $1.7 million in Q4 2025 for Lucid Diagnostics, up from $1.3 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $3.5 million in Q4 2021 to a low of $1.3 million in Q2 2025.
  • Median Research & Development over the past 5 years was $1.8 million (2021), compared with a mean of $2.0 million.
  • Biggest five-year swings in Research & Development: skyrocketed 83.66% in 2022 and later crashed 46.89% in 2023.
  • Lucid Diagnostics' Research & Development stood at $3.5 million in 2021, then fell by 29.87% to $2.4 million in 2022, then dropped by 21.46% to $1.9 million in 2023, then dropped by 24.24% to $1.5 million in 2024, then grew by 18.58% to $1.7 million in 2025.
  • The last three reported values for Research & Development were $1.7 million (Q4 2025), $1.3 million (Q3 2025), and $1.3 million (Q2 2025) per Business Quant data.